Bempedoic acid plus ezetimibe is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet (a) in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe (b) alone in patients who are either statin – intolerant or for whom a statin is contraindicated and are unable to reach LDL-C goals with ezetimibe alone and (c) in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||15/06/2020|
|Rapid review completed||03/07/2020|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of of bempedoic acid + ezetimibe (Nustendi®) compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||06/07/2020|
|Pre submission consultation with Applicant||22/09/2020|
|Current Status||Awaiting HTA submission from Applicant|